Abstract
Introduction: Collateral ventilation (CV) has been shown to prevent lung volume reduction (LVR) after Endobronchial Valve (EBV) treatment. Direct measurement of CV may predict patients who will achieve significant LVR. The Chartis® Pulmonary Assessment System quantifies the average collateral resistance. When the resistance value >10, the patient is “CV Negative;” when the resistance value ≤10, the patient is “CV Negative;”.
Objective: To evaluate the effectiveness of the Chartis® system in predicting subjects with heterogeneous emphysema who will achieve significant (≥350mL) LVR from EBV therapy.
Methods: Patients with heterogenous emphysema were enrolled. Following Chartis assessment of the targeted lobe, that was determined by using HRCT, all patients were treated with Zephyr® EBV. Primary endpoint was HRCT-measured LVR in the treated lobe at 30-days. FEV1, SGRQ and 6MWT were evaluated as secondary endpoints.
Results: To date, primary endpoint is collected for 24 patients. Primary and Secondary Endpoints for 75-80 patients are anticipated. Subgroup analyses will focus on patient selection criteria.
Conclusion: Chartis System predicts significant LVR after EBV treatment. Results suggest that expanded patient selection criteria will enable successful treatment for a broader population of emphysema patients.
- © 2011 ERS